Feliciano Serrano, MD
Nephrology · Huntington Park, CANPI 1649225558
Payments from drug & device makers
Across 370 payments — averaging $406.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$140K
- Abbott$2K
- Amgen$1K
- ANI Pharmaceuticals, Inc.$780
- Mallinckrodt Hospital Products Inc.$672
- AstraZeneca$598
- plus $4K from 21 others
What the payments were for
- Travel & lodging$9301%
- Food & beverage$9,2186%
- Education$20,20713%
- Other$120,00080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 13 | $140,430 |
| Abbott | 31 | $2,347 |
| Amgen(2 entities) | 53 | $1,140 |
| ANI Pharmaceuticals, Inc. | 52 | $780 |
| Mallinckrodt Hospital Products Inc. | 17 | $672 |
| AstraZeneca | 31 | $598 |
| Bayer | 24 | $568 |
| Bard Peripheral Vascular, Inc. | 15 | $520 |
| Fresenius USA Marketing, Inc. | 28 | $501 |
| Philips North America LLC | 18 | $497 |
| Boston Scientific | 5 | $456 |
| Calliditas Therapeutics US Inc. | 22 | $446 |
| Akebia Therapeutics Inc | 17 | $349 |
| Vifor Pharma, Inc. | 13 | $265 |
| Curonix LLC | 4 | $165 |
| Mallinckrodt Enterprises LLC | 6 | $140 |
| Travere Therapeutics, Inc. | 4 | $101 |
| Aurinia Pharma U.S., Inc. | 4 | $93 |
| OPKO Pharmaceuticals, LLC | 3 | $73 |
| Novo Nordisk | 3 | $60 |
| BD | 1 | $30 |
| Ardelyx, Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Organogenesis Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$139,793
- Omnilink Elite vascular stent system$1,185
- ABSOLUTE PRO$300
- ACTHAR$260
- ROTAPRO$169
- VenaCure 1470 Pro$165
- Turbo Elite$134
- Tavneos$125
- Kerendia$125
- Absolute Pro vascular stent system$123
How this compares
$150,354 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 69 | $143,782 |
| KerendiaFinerenone | 67 | $45,484 |
| LokelmaSodium Zirconium Cyclosilicate | 46 | $30,948 |
| EpogenEpoetin Alfa | 44 | $27,020 |
| FarxigaDapagliflozin Propanediol | 29 | $21,350 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $18,258 |
| DapagliflozinDapagliflozin Propanediol | 33 | $17,825 |
| EliquisApixaban | 16 | $9,293 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,233 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 22 | $4,431 |
| ProsolParenteral Amino Acid 20% No.1 | 11 | $1,914 |
| Sevelamer Carbonate | 12 | $1,017 |
| Labetalol Hcl | 20 | $844 |
| Gabapentin | 48 | $464 |
| Benazepril Hcl | 53 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $501 | $143,78269 claims |
| AstraZenecaLokelma, Farxiga | $598 | $52,29875 claims |
| BayerKerendia | $568 | $45,48467 claims |
| AmgenEpogen | $1,140 | $27,02044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.
Other nephrology in Huntington Park
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.